NEW YORK (GenomeWeb) – MDNA Life Sciences announced today that it has signed an agreement making BL&H the exclusive South Korean distributor of its PCR-based liquid biopsy prostate cancer test, the Prostate Mitomic Test (PMT).

PMT analyzes the mitochondrial genome to determine which men with clinical suspicion of prostate cancer are likely to have high-grade disease that may require immediate intervention. The test's negative predictive value can also help identify cases that can safely delay or forego immediate biopsy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.